Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE, on behalf of the EFC6018 GetGoal-Mono Study Investigators
68 Semaglutide reduced the risk of incident (0.28% vs
According to FDA, GLP-1RA had not shown evident risk of pancreatitis and pancreatic tumor (111)
doi: 10.3389/fimmu.2025.1687755 Received 18 August 2025 Revised 26 October 2025 Accepted 17 November 2025 Published 16 December 2025 Volume 16 - 2025 Edited by Karina Pino-Lagos, University of the Andes, Chile Reviewed by Jaxaira Maggi, Spanish National Research Council (CSIC), Spain Noymar Luque-Campos, INSERM U1183 Institut de Mdecine Rgnratrice et de Biothrapie (IRMB), France Updates Copyright 2025 Hu, Zhao, Dai, Wu, Tang, Zhang, Jiang, Rui and Liu